Merck Sharp + Dohme Corp.

Maria T Cruanes

Laman L Alani

Soumojeet Ghosh

Wei Xu

Laura Marie Artino

Saurabh A Palkar

Bhagwant Rege

Craig A McKelvey

Nazaneen Pourkavoos

James R Ney

Yunhui Wu

Honggang Zhu

Agam R Sheth

Craig A Mckelvey

Pharmaceutical formulations suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a base salt of a compound of Formula (I) and a release rate controlling composition comprising a solubilizing agent, a gelling agent, and a water soluble filler; wherein R, R, Rand Rare defined herein. The formulations are suitable for use in the inhibition of HIV integrase, the treatment and prophylaxis of HIV infection, and the treatment, prophylaxis and delay in the onset of AIDS.

Pharmaceutical formulation containing a release rate controlling composition

Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.

Pharmaceutical composition containing an anti-nucleating agent

A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)&#x3e;10. 

Self-emulsifying formulations of CETP inhibitors

Growing community of inventors

Lansdale, PA, United States of America

Maria T Cruanes